Browse Biomarkers Based on Source

This page shows data for Serum source.
Total Entries Retrieved: 354
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
18 Insulin Like Growth Factor-1 (IGF-1) Protein Mice Downregulated in SPI (soy protein isolate) diet: [Control: (223 ±61ng/ml; SPI Diet: 349 ±40 ng/ml ) Prognostic PCa Mice fed Control Diet Vs PCa Mice fed soy protein isolate Diet p<0.05 Serum 10460196
28 Insulin Protein Humans Upregulated in High Risk Group Prognostic High vs (Medium and Low) Risk p= 0.05 Serum 11757030
32 Triiodothyronine Protein Humans Upregulated in Prostate Cancer (Control: 72 ±24.9; PCa: 83.9 ±18.1) Diagnostic Normal Prostate vs Localised Prostate Cancer p = 0.048 Serum 12441933
33 Triiodothyronine Protein Humans Upregulated in Prostate Cancer (PCa: 83.9 ±18.1 vs BPH: 94.4±12.3) Diagnostic Localised Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.013 Serum 12441933
34 Triiodothyronine Protein Humans Upregulated in High Risk Group Prognostic High vs Moderate Risk Group p=0.041 Serum 12497024
35 Triiodothyronine Protein Humans Upregulated in High Risk Group Prognostic High vs Low Risk Group p=0.013 Serum 12497024
36 Lycopene Protein Humans Downregulated (41% fold) Diagnostic Normal vs Cancerous p<0.05 Serum 12497123
94 E-cadherin Protein Humans Upregulated in Localised PCa (BPH: 7.26; Localised PCa: 9.46) Diagnostic Benign Prostatic Hyperplasia (BPH) Vs Localised PCa p=0.011 Serum 15870707
95 E-cadherin Protein Humans Upregulated in Metastatic PCa: (Localised PCa: 9.46; Metastatic PCa: 27.49) Prognostic Localised PCa Vs Metastatic PCa p<0.001 Serum 15870707
96 E-cadherin Protein Humans Iincreased risk of late biochemical failure with high expression Prognostic Biochemical Faliure Vs No Biochemical Faliure p<0.05 Serum 15870707
101 bromo domain containing protein 2 (BRD2),+eukaryotic translation initiation factor 4 gamma 1 (EIF4G1)+ribosomal protein L22 (RPL22)+ribosomal protein L13a (RPL13a)+17 other autoantibodies mRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Controls p<0.05 Serum 16177248
107 18 proteins with Mass (Da) M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031+ M5265 +M15878 + M16003 + M16068 Protein Humans Downregulated in PCa: [M3700 + M3904 + M3978 + M4300 + M5085 + M5923 + M6250 + M6569+ M6652 + M7121 + M7782 +M7850 + M7991 + M95031Upregulated in PCa: [M5265 +M15878 + M16003 + M16068] Diagnostic Prostate Cancer Vs Controls p<0.01 Serum 16372118
108 FPA Protein Humans Downregulated (0.58 fold) Diagnostic Normal vs Prostate Cancer p=0.000108 Serum 16395409
109 Fibrogen alpha Protein Humans Downregulated (0.33 fold) Diagnostic Normal vs Prostate Cancer p=0.00000000000763 Serum 16395409
110 inter-α-trypsin inhibitor heavy chain H4 (ITIH4) Protein Humans Upregulated (121 fold) Diagnostic Normal vs Prostate Cancer p=0.0000108 Serum 16395409
111 Clusterin Beta Protein Humans Upregulated (251 fold) Diagnostic Normal vs Prostate Cancer p=0.00000000481 Serum 16395409
112 factor X111a Protein Humans Upregulated (2.84 fold) Diagnostic Normal vs Prostate Cancer p=0.0000000143 Serum 16395409
120 ICTP Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
121 BSAP Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
122 TRAP5b Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
131 PTGS2 Other Humans Upregulated in PCa [(Mean Values) PCa: 85.95; BPH: 25.26] Diagnostic Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer (PCa) P<0.0001 Serum 17764114
132 PTGS2 Other Humans Upregulated in PCa [(Mean Values) PCa: 85.95; Healthy Individuals: 10.88] Diagnostic Prostate Cancer (PCa) Vs Healthy Individuals P<0.0001 Serum 17764114
133 PTGS2 Other Humans Increased expression with increase in relapse Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p = 0.0395 Serum 17764114
137 β-2-Microglobulin Protein Humans Upregulated in Metastatic Prostate Cancer (Controls: 1.9± 0.6; Metastatic Castrate PCa: 2.7 ± 1.1) Diagnostic Controls Vs Metastatic Castrate Prostate Cancer p<0.05 Serum 17404077
220 VEGF (Vascular Endothelial Growth Factor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
221 Resistin Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.04 Serum 17932343
222 IL-1Ra (Interleukin 1Ra) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.03 Serum 17932343
223 MMP-3 (Matrix Metalloproteinase-3) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
224 PAI-1(active) (Plasminogen Activator Inhibitor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.01 Serum 17932343
225 AFP (α- Fetoprotein) Protein Humans Upregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.02 Serum 17932343
226 Kallikrein-8 Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.02 Serum 17932343
227 PSA Protein Humans Upregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.0001 Serum 17932343
228 G-CSF (Granulocyte Colony-Stimulating Factor) Protein Humans Downregulated in Prostate Cancer Diagnostic Cancerous Vs Normal Patients p=0.005 Serum 17932343
239 Anterior Gradient 2 Homolog AGR2 Protein Humans Upregulatated in PCa (3.8 fold) Diagnostic Normal Vs Prostate Cancer p=0.0021 Serum 18061988
240 YKL- 40 Protein Humans Upregulated in PCa (PPC: 188.01 Vs BPH: 73.54 ± 9.25) Diagnostic Benign Prostatic Hyperplasia vs Primary Prostate Cancer p<0.001 Serum 18190830
241 Chitotriosidase Protein Humans Upregulated in PCa (PCa: 91.33 ± 8.32 Vs BPH: 69.72 ±8.69) Diagnostic Normal (Control) Vs Cancer (High Gleason Grade) p<0.05 Serum 18190830
242 CXCL12 Protein Humans Upregulated in Biopsy Positive Patients Diagnostic Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer p=0.05 Serum 18196514
284 %[-2]proPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.001 Serum 18550118
285 PSA+BPSA+%fPSA+%[-2] proPSA+[-2]proPSA/BPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p<0.05 Serum 18550118
286 %fPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.008 Serum 18550118
410 Methylation Status of RARB2 Methylation Humans Methylated in Stage IV PCa Prognostic PCa stage I-III VS PCa Stage IV p=0.027 Serum 19131636
411 Methylation Status of GSTP1 Methylation Humans Methylated in Stage IV PCa Prognostic PCA stage I-III VS PCA Stage IV p=0.019 Serum 19131636
412 Methylation Status of GSTP1+RARB2 Methylation Humans Methylated in Stage IV PCa Prognostic PCA stage I-III VS PCA Stage IV p=0.019 Serum 19131636
413 PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI Protein Humans Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI] Prognostic Recurrence Vs No recurrence for 5 years Training: p=0.012 Testing: p=0.011 Serum 19157448
458 Prostate specific antigen (PSA), Prostate Specific Membrane Antigen (PSMA), Platelet Factor-4 (PF-4), and Interleukin-6 (IL-6) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Female Controls NA Serum 19775154
462 Hepatocyte Growth Factor (HGF) Protein Humans Downregulated after Polyphenon E treatment(18.9%) Predictive Before Vs After Polyphenon E treatment p<0.001 Serum 19542190
463 Vascular Endothelial Growth Factor (VEGF) Protein Humans Downregulated after Polyphenon E treatment(9.9%) Predictive Before Vs After Polyphenon E treatment p=0.032 Serum 19542190
464 Insulin Like Growth Factor (IGF-I) Protein Humans Downregulated after Polyphenon E treatment(10.4%) Predictive Before Vs After Polyphenon E treatment p=0.012 Serum 19542190
465 IGF Binding Protein-3 (IGFBP-3) Protein Humans Downregulated after Polyphenon E treatment(11%) Predictive Before Vs After Polyphenon E treatment p=0.024 Serum 19542190
466 Prostate Specific Antigen (PSA) Protein Humans Downregulated after Polyphenon E treatment(7.9%) Predictive Before Vs After Polyphenon E treatment p=0.009 Serum 19542190
467 IGF-I/IGFBP-3 Protein Humans Downregulated after Polyphenon E treatment(3.4%) Predictive Before Vs After Polyphenon E treatment p=0.028 Serum 19542190
478 Clusterin and Clusterin Density Protein Humans Upregulated: Clusterin [(BPH: 94.2 ± 38.7) Vs (PCA: 137.2 ± 36.6 )]; Clusterin Density [(BPH: 3.2 ± 2.2 ) Vs (PCA: 5.5 ± 2.6 )] Diagnostic Benign Prostatic Hyperplasia Vs Prostate Cancer p<0.001 Serum 19854485
479 Clusterin & Clusterin Density Protein Humans Upregulated: Clusterin [(No Metastasis 131.1 ± 32.1) Vs (Metastasis: 151.3 ± 34.6 )]; Clusterin Density [(No Metastasis: 5.1 ± 2.3 ) Vs (Metastasis: 6.2 ± 2.7 )] Prognostic No Metastasis Vs Metastasis p<0.001 Serum 19854485
480 Clusterin Density Protein Humans Upregulated: Clusterin Density [(ExtraProstatic 6.2 ± 2.4) Vs (Organ-confined disease: 5.4 ± 2.2 )]; Prognostic Organ-confined disease Vs Extraprostatic disease p=0.033 Serum 19854485
481 Clusterin Density Protein Humans Decreased expression in Patients with Biochemical Recurrence free Survival Prognostic Biochemical Recurrence Free Survival Vs No Survial p=0.034 Serum 19854485
482 PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Tumor p<0.05 Serum 20632177
483 MMP-2 Protein Humans Upregulated and Hypermethylated (PCa: 684.65 ± 129.36; Normal: 609.63 ± 172.58) Diagnostic Prostate Cancer Vs No Tumor p=0.038 Serum 20632177
484 PSA+MMP-2+ AMACR + Methylation Status of (GSTP1 or RASSF1A) Protein + DNA Humans Upregulated and Hypermethylated in PCa Diagnostic Prostate Cancer Vs No Tumor p=0.036 Urine and Serum 20632177
496 e-FABP5 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Serum 19894759
497 e-FABP5 Protein Humans Upregulated in Localised PCA Diagnostic Localized PCa and BPH p<0.01 Serum 19894759
515 p2PSA ([-2]isoform of proenzyme prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample p = 0.0006 Serum 20171670
516 %fPSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample p=0.02 Serum 20171670
517 prostate specific antigen Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample NA Serum 20171670
518 Prostate Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Sample NA Serum 20171670
523 hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227; miRNA Humans Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1]; Prognostic Localised Vs Metastatic Prostate Cancer p<0.0098 Serum 20473869
524 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Differentially Expressed Prognostic Pathoglical Stage pt3 vs pt2 p<0.05 Serum 20473869
525 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Upregulated Prognostic Gleason Score 6 Vs Gleason Score 7 p<0.05 Serum 20473869
526 miRNA-375 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.01 Serum 20473869
527 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.05 Serum 20473869
528 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Gleason Score >8 Vs Gleason Score 7 p<0.01 Serum 20473869
551 Total sialic acid Metabolites Humans Upregulated (mg/dL): (Controls: 6.25±3.49) Vs (Prostate Cancer: 15.1±4.83) Diagnostic Control Vs Cancer p<0.001 Serum 20973404
552 Total sialic acid Metabolites Humans Upregulated (mg/dL): (BPH: 7.24±4.56) Vs (Prostate Cancer: 15.1±4.83) Diagnostic BPH Vs Cancer p<0.001 Serum 20973404
553 Cathepsin D Protein Humans Upregulated (pmol/mL): (Controls: 4.85±1.35) Vs (Prostate Cancer: 9.2±1.75) Diagnostic Control Vs Cancer p<0.001 Serum 20973404
554 Cathepsin D Protein Humans Upregulated (pmol/mL): (BPH: 5.11±1.17) Vs (Prostate Cancer: 9.2±1.75) Diagnostic BPH Vs Cancer p<0.001 Serum 20973404
563 freePSA (free prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
564 [-2]proPSA ([-2]proenzyme prostate specific antigen) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
565 %fPSA (%free prostate specific antigen) Protein Humans Downregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
566 DKK1 (Dickkopf-1) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
567 NEM (neuroendocrine marker) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
568 Prostate Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Control Vs Cancer p<0.05 Serum 21074193
570 miR-874, -1274a, -1207-5p, -93, and -106a miRNA Humans Upregulated in PCa Diagnostic Healthy Vs Prostate Cancer miR-874 p<0.00; miR-1274a p<0.001; miR-1207-5p p<0.001; miR-93 p<0.001; miR-106a p<0.001 Serum 21098088
571 miR- 223, -26b, -30c, and -24 miRNA Humans Downregulated in PCa Diagnostic Healthy Vs Prostate Cancer miR-30c p= 0.01; miR-26b p<0.001; miR-223 p<0.001; miR-24 p= 0.005; Serum 21098088
572 miR-106a, miR-93 and -1274a; miR-451; miR-1207-5p; miR-874 miRNA Humans Upregulated in PCa Diagnostic Healthy Vs High Risk (CAPRA>5) miR-106a p<0.001, miR-93 p<0.001; miR-1274a p<0.001; miR-451 p= 0.02; miR-1207-5p p<0.001; miR-874 p= 0.003 Serum 21098088
573 miR-223; miR-24; miRNA Humans Downregulated in PCa Diagnostic Healthy Vs High Risk (CAPRA>5) miR-223 p= 0.002; miR-24 p=0.02 Serum 21098088
574 Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 Protein Humans Upregulated in PCa Diagnostic BPH vs Prostate Cancer NA Serum 21166384
575 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H + Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
576 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
577 Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 Protein Humans Upregulated Diagnostic BPH vs Prostate Cancer NA Serum 21166384
578 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H +Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
579 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
626 fPSA Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.024 Serum 21482022
627 %fPSA Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.008 Serum 21482022
628 PSA Density Protein Humans NA Diagnostic Prostate Cancer Vs Controls p=0.001 Serum 21482022
629 %p2PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
630 Prostat Health Index (phi) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
631 Base Model (Age+ Prostate Volume + tPSA+ fPSA) Protein Humans NA Diagnostic Prostate Cancer Vs Controls Not significant Serum 21482022
632 Base Model + %p2PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
633 Base Model + phi Protein Humans Upregulated in PCa (phi) Diagnostic Prostate Cancer Vs Controls p < 0.001 Serum 21482022
634 NY-ESO-1 + XAGE-1b + SSX-2,4 + AMACR + p90 + LEDGF + PSA Index Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs BPH LEDGF, p90, SSX-2, 4, XAGE-1b: p<0.001; NY-ESO-1: p=0.029; AMACR: NS Serum 21504557
635 PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs BPH p<0.05 Serum 21504557
653 Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score Protein Humans Downregulated in Patients with Gleason Score Upgradation Prognostic Gleason Score Upgradation Vs No Gleason Score Upgradation p = 0.024 Serum 21520165
654 Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score Protein Humans Downregulated in Patients with Gleason Score Upgradation Prognostic Gleason Score Upgradation Vs No Gleason Score Upgradation NA Serum 21520165
682 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (12 months) NA Serum 21741162
683 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (24 months) NA Serum 21741162
684 PVRL1 (poliovirus receptor-related 1); PRG4 (proteoglycan 4); AP (alkaline phosphatase); FSTL1 (follistatin-like 1); Albumin; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1); ANPEP (alanyl (membrane) aminopeptidase); CRP (C-reactive protein); Hb (hemoglobin); CADM1a (cell adhesion molecule 1a); POSTN (periostin, osteoblast specific factor); CADM1b (cell adhesion molecule 1b); CP (ceruloplasmin); AZGP1 (alpha-2-glycoprotein 1, zinc-binding). Protein Humans NA Prognostic Overall Survival Vs No Survival PVRL1 (poliovirus receptor-related 1) p= 0.002; CD10 p= 0.004; PRG4 (proteoglycan 4) p = 0.006; AP (alkaline phosphatase) p= 0.007; FSTL1 (follistatin-like 1) p= 0.01; Albumin p= 0.016; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1) p = 0.018; ANPEP (alanyl (membrane) aminopeptidase) p=0.02; CRP (C-reactive protein) p= 0.02; Hb (hemoglobin) p=0.022; CADM1a (cell adhesion molecule 1a) p =0.03; POSTN (periostin, osteoblast specific factor) p=0.034; CADM1b (cell adhesion molecule 1b) p=0.035; CP (ceruloplasmin) p =0.046; AZGP1 (alpha-2-glycoprotein 1, zinc-binding) p =0.046. Serum 21741162
706 α2-macroglobulin (α2M) Protein Humans Upregulated (Healthy: 151.7±25.30 Vs without α2M deficiency: 252.45±125.07) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
707 C-reactive protein (CRP) Protein Humans Upregulated (Healthy: 109.58±89.66 Vs without α2M deficiency: 1534.6±1482.8) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
708 serum amyloid A (SAA) Protein Humans Upregulated (Healthy: 9.96±4.16 Vs without α2M deficiency: 54.7±44.5) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
709 interleukin-6 (IL-6) Protein Humans Upregulated (Healthy: 7.58±6.0 Vs without α2M deficiency: 46.50±40.65) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.01 Serum 21894431
710 α1 anti-chymotripsin (α1AT) Protein Humans Upregulated (Healthy: 122±28.0 Vs without α2M deficiency: 293.76±68.51) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.05 Serum 21894431
711 α1 acid glycoprotein (α1AG) Protein Humans Upregulated (Healthy: 67.5±25.5 Vs without α2M deficiency: 102±39.36) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.05 Serum 21894431
712 Ceruloplasmin (CP) Protein Humans Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.74±10.93) Diagnostic healthy controls vs. PCa patients without α2M deficiency; p<0.05 Serum 21894431
713 α2-macroglobulin (α2M) Protein Humans Downregulated with α2M deficiency (Without α2M deficiency: 252.45±125.07 Vs with α2M deficiency: 12.75±5.60) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
714 C-reactive protein (CRP) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 1534.6±1482.8 Vs with α2M deficiency: 173±90.3) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
715 serum amyloid A (SAA) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 54.7±44.5 Vs with α2M deficiency: 2.15±1.68) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
716 interleukin-6 (IL-6) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 46.50±40.65 Vs with α2M deficiency: 3.38±2.61) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
717 α1 anti-chymotripsin (α1AT) Protein Humans Upregulated (Healthy: 122±28.0 Vs with α2M deficiency: 293.76±68.51) Diagnostic Healthy controls vs. PCa patients with α2M deficiency p<0.05 Serum 21894431
718 α1 acid glycoprotein (α1AG) Protein Humans Upregulated (Healthy: 67.5±25.5 Vs with α2M deficiency: 100.8±38.90) Diagnostic Healthy controls vs. PCa patients with α2M deficiency p<0.05 Serum 21894431
719 Ceruloplasmin (CP) Protein Humans Upregulated (Healthy: 29.0±8.0 Vs without α2M deficiency: 37.6±10.89) Diagnostic Healthy controls vs. PCa patients with α2M deficiency p<0.05 Serum 21894431
763 tPSA mRNA Humans Upregulated in Cancerous Conditions (PCA: Median: 7.51; BPH: Median: 4.15) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.05 Serum 21963599
775 Vitamin -C Protein Humans Downregulated in PCA Diagnostic Controls Vs Patients p<0.05 Serum 21993000
776 Vitamin -E Protein Humans Downregulated in PCA Diagnostic Controls Vs Patients p<0.05 Serum 21993000
778 Vitamin -C Protein Humans Downregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Serum 21993000
779 Vitamin -E Protein Humans Downregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Serum 21993000
781 Vitamin -C Protein Humans Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) Serum 21993000
782 Vitamin -E Protein Humans Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with no Treatment) Serum 21993000
784 Vitamin -C Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>8 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Serum 21993000
785 Vitamin -E Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>9 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Serum 21993000
787 Auto-antibody profile (TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes) Protein (Auto-antibodies) Humans Upregulated in PCa Diagnostic prostate cancer Vs benign disease p<0.001 Serum 22012634
788 TTLL12+VAT1L+GGA1+RPIA+NHSL1+NOVA2+MAP2+PRPF38B+SRP14+ HSPH1+ZNF154+ADD1+RASSF7+RBM15+394 other genes Protein (Auto-antibodies) Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men p<0.001 Serum 22012634
789 tPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
790 cPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
791 f/tPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
792 c/tPSA Protein Humans Upregulated in PCa Diagnostic PCa VS Benign Prostatic Hyperplasia p≤ 0.05 Serum 22024423
793 Cholesterol Lipid Humans Upregulated in Fish Oil Diet Predictive Change in Western Diet VS Change in Fish Oil Diet in Patients with PCa 0.005 Serum 22027686
794 Triglycerides Lipid Humans Upregulated in Fish Oil Diet Predictive Change in Western Diet VS Change in Fish Oil Diet in Patients with PCa p < 0.001 Serum 22027686
795 mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-215; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887 miRNA Mice Upregulated: [mmu-mir-24; mmu-mir-141; mmu-mir-182; mmu-mir-184; mmu-mir-298; mmu-mir-320; mmu-mir-346; mmu-mir-375; mmu-mir-887]; Downregulated: [mmu-mir-215] Diagnostic TRAMP and wild-type (WT) littermate control mice p≤ 0.05 Serum 22052531
796 hsa-mir-141; hsa-mir-298; hsa-mir-375 miRNA Humans Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-375] Diagnostic Normal Vs Primary Tumor p≤ 0.05 Serum 22052531
797 hsa-mir-141; hsa-mir-298; hsa-mir-346; hsa-mir-375 miRNA Humans Upregulated in PCa [hsa-mir-141; hsa-mir-298; hsa-mir-346 ; hsa-mir-375] Diagnostic Normal Vs Metastatic Tumor p≤ 0.05 Serum 22052531
798 hsa-mir-375 miRNA Humans High expression associated with an increased risk of BCR Prognostic Biochemical Recurrenece p = 0.002 Serum 22052531
799 hsa-mir-375 miRNA Humans High expression with reduced chances of relapse free survival Prognostic Biochemical Recurrenece Univariate: p=0.0001; Multivariate: p=0.0260 Serum 22052531
817 Interleukin-18 (IL-18) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
818 Interleukin-10 (IL-10) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 2.08 ± 0.27; BPH: 2.15 ± 0.18; TNM Stage 2: 8.03 ± 0.49; TNM Stage 3: 13.06 ± 0.45; TNM Stage 4: 6.32 ± 0.29] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
819 Interleukin-18 (IL-18) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
820 Interleukin-10 (IL-10) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
827 Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1) Protein Humans Differentially Expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p< 0.05 Serum 22146597
828 TARDBP; TLN1; ;PARK7; LEDGF/PSIP1; CALD1; p73; PTEN; PXN; PEX10; KLK3; DBN1; NFAT1; B Tubulin; SOS1; HSF4; TOP1; HSPA1A/B; Protein Humans Differentially Expressed Diagnostic prostate cancer Vs benign prostatic hyperplasia p< 0.05 Serum 22146597
831 sPLA2-IIA (Secreted group IIA phospholipase A2) Protein Humans Upregulated in Prostate cancer Diagnostic Controls Vs Prostate Cancer p<0.001 Serum 22189868
832 CRP (C- Reactive Protein) Protein Humans Upregulated in Prostate cancer Diagnostic Controls Vs Prostate Cancer p<0.001 Serum 22189868
868 Alpha2- macroglobin (α2m); Elongation Factor 1A (EFA1) ; Lumican ; Complement Factor 1 Light Chain; Heparin Cofactor 2; Inter-alpha-trypsin inhbitor heavy chain H2; Serum amyloid P-component; Histidine Rich gylcoprotien; Transthyretin Protein Humans Upregulated: [Alpha2- macroglobin (α2m) (1.4 fold); Elongation Factor 1A (EFA1) (1.2 fold); Lumican (1.1 fold); Downregulated: [Complement Factor 1 Light Chain (1.1 fold); Heparin Cofactor 2 (1.1 fold) ; Inter-alpha-trypsin inhbitor heavy chain H2 (1.1 fold) ; Serum amyloid P-component (1.1 fold); Histidine Rich gylcoprotien (1.3 fold) ; Transthyretin (1.4 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
869 Beta-2-gylcoprotien 1 + Somatomedin- B Protein Humans Upregulated: [Beta-2-gylcoprotien 1 (1.2 fold)+ Somatomedin- B (1.1 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
870 Antithrombin III + Inter-alpha-trypsin inhibitor heavy chain H3 Protein Humans Downregulated: [Antithrombin III (1.4 fold)+ Inter-alpha-trypsin inhibitor heavy chain H3 (1.7 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
871 Afamin + Fibronectin 1 + Alpha-2-HS-glycoprotien chain B Protein Humans Upregulated : [Afamin (1.4 fold) + Fibronectin 1 (1.4 fold) + Alpha-2-HS-glycoprotien chain B (1.1 fold)] Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
872 cDNA FLJ55673 + cDNA FLJ58564 + Ceruplasmin + Complement C5 + Alpha-1-antichymotrypsin + Complement component C9b + cDNA FLJ54228 Protein Humans Downregulated : [cDNA FLJ55673 (1.1 fold)+ cDNA FLJ58564 (1.1 fold)+ Ceruplasmin (1.1 fold) + Complement C5 (1.1 fold) + Alpha-1-antichymotrypsin (1.2 fold) + Complement component C9b (1.2 fold) + cDNA FLJ54228 (1.5 fold) Diagnostic BPH Vs Non Progressing Prostate Cancer p ≤0.01 Serum 22355332
873 cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3 Protein Humans Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
874 Inter-alpha-trypsin inhibitor heavy chain H3 + Antithrombin III Protein Humans Upregulated [Inter-alpha-trypsin inhibitor heavy chain H3 (2.0 fold) + Antithrombin III (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
875 Apliopoprotien A-IV + Complement Component 4B Protein Humans Downregulated [Apliopoprotien A-IV (1.1 fold)+ Complement Component 4B (1.3 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
876 Beta 2-Glycoprotein 1 + Somatomedin- B Protein Humans Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
877 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.2 fold) + Afamin (1.5 fold)+ Fibronectin 1 (1.6 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
878 Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin Protein Humans Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
879 Apliopoprotien A-IV + Complement Component 4B Protein Humans Upregulated [Apliopoprotien A-IV (1.3 fold) + Complement Component 4B (1.4 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
880 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
881 cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673 Protein Humans Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
897 Macroglobulin α2 ; HP protein; CLU precursor; Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region; Protein Humans Upregulated [>1.5 fold]: (Macroglobulin α2 ; HP protein; CLU precursor; ) Downregulated: [1.5 fold] (Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;) Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
898 Transthyretin (TTR) Protein Humans Downregulated (1.58 fold ) in Post AAT patients Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
899 Clusterin (CLU) Protein Humans Upregulated (1.51 fold ) in Post AAT patients Predictive Before and after androgen ablation therapy (AAT) p<0.01 Serum 22496929
902 (Table 1) Protein Humans Upregulated in PCa [1.12-2.25] Diagnostic Patients Vs Controls p<0.05 Serum 22499197
907 %p2PSA Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group; PCa Vs HGPIN group p<0.001 Serum 22542564
908 (percent free PSA) % fPSA Protein Humans Downregulated in PCa [No PCa: 19.36 ; PCa: 15.41; HGPIN: 22.23] Diagnostic PCa VS No PCa group; PCa Vs HGPIN group No PCa Vs PCa:p=0.004; PCa Vs HGPIN: p<0.001 Serum 22542564
909 Prostate Health Index (phi) Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group; PCa Vs HGPIN group p< 0.001 Serum 22542564
929 Spondin-2 (SPON2) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Healthy Men p=0.001 Serum 22615945
930 Triosephosphate isomerase 1 (TPI1); Spondin-2 (SPON-2); Thrombospondin 1, N-Terminal Domain (THBS1); Phosphoglycerate mutase 1 (PGAM1); Syndecan binding protein 1 (ST1); Peroxiredoxin 1 (PRDX1); Nucleophosmin- isoform CRA_c (NPM1) Protein Cell Lines Differentially Expressed in PCA Diagnostic BPH-1, LNCaP Vs C4-2 p<0.05 Serum 22615945
940 Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR) Protein Humans Downregulated in PCa [Apolipoprotein A-II (APOA2); Complement C3 (C3f); Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4f); ] Upregulated in PCa [Alpha-1 antitrypsin (AAT); High molecular weight kininogen (KNG); Transthyretin (TTR)] Diagnostic Benign Prostatic Hyperplasia (BPH) Vs Prostate Cancer (PCa) p<0.01 Serum 22740474
961 Prostate health index (phi) Protein Humans Upregulated in PCa [No PCa: 36.84 (28.82–46.14) Vs PCa 49.97 (37.75–69.65)] Diagnostic PCa Vs No-PCa <0.001 Serum 22821756
963 PCA3 + phi mRNA Humans Upregulated in PCa Diagnostic PCa Vs No-PCa p=0.001 Urine + Serum 22821756
964 Soluble interleukin-6 Receptor (sIL-6R) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.024 Serum 22866141
965 Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.011 Serum 22866141
966 Osteopontin Protein Humans Upregulated in PCa Diagnostic PCa Vs Controls (Healthy Donors + BPH) p<0.05 Serum 22870138
969 hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489 miRNA Humans Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ] Prognostic LowRisk(LR) Vs Metastatic CRPC p<0.0001 Serum 22887127
972 Prostate Specific Antigen (PSA) Protein Humans Downregulated with Increased BMI: [BMI <23: 9.49±3.46 Vs BMI >25: 6.28±1.36] Prognostic BMI Group <23 Vs BMI Group >25 p=0.001 Serum 22901185
973 Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa [Patients: 7.8±3; Controls: 1.9±0.98] Diagnostic Prostate Cancer Vs Controls p<0.001 Serum 22901185
974 ACP Protein Humans Upregulated in PCa [Patients: 4.8±1.8; Controls: 3.1±0.6] Diagnostic Prostate Cancer Vs Controls p<0.001 Serum 22901185
975 PAP Protein Humans Upregulated in PCa [Patients: 2.0±1.7 Controls: 0.5±0.2] Diagnostic Prostate Cancer Vs Controls p<0.001 Serum 22901185
989 Zinc α2-glycoprotein (ZAG) + PSA Protein Humans Upregulated in PCa Diagnostic PCA VS No PCA group p=0.05 Urine + Serum 23020913
1013 Survivn Protein Humans Upregulated in PCA (150 pg/ml ) compared to both Healthy controls (59.7 pg/ml) and BPH (55 pg/ml) Diagnostic (Normal and BPH )VS PCa p<0.001 Serum 23091600
1024 Serum PSA Protein Humans NA Prognostic PCa Vs No PCA group p<0.001 Serum 23201468
1025 Serum PSA Protein Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p = 0.003 Serum 23201468
1026 Serum PSA Protein Humans NA Prognostic Tumor Stage (T3-T4) p = 0.002 Serum 23201468
1032 C-terminal telopeptide Protein Humans Downregulated in patients with PCa treated with with Risedronate (Placebo: 138.16± 26.71; Risedronate: 18.24 ± 22.38) Predictive Placebo vs Risedronate (after 24 months) p =0.0014 Serum 23265571
1033 Bone-specific alkaline phosphatase Protein Humans Downregulated in patients with PCa treated with with Risedronate (Placebo: 60.29 ± 10.28; Risedronate: 9.94 ± 6.95) Predictive Placebo vs Risedronate (after 24 months) p =0.0002 Serum 23265571
1034 N-Mid-Osteocalcin Protein Humans Downregulated in patients with PCa treated with with Risedronate (Placebo: 100.35 ± 30.4; Risedronate: 18.85 ± 10.8) Predictive Placebo vs Risedronate (after 24 months) p =0.0173 Serum 23265571
1035 BMI1 Protein Humans Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44) Prognostic Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer p< 0.001 Serum 23308129
1047 Prostate Specific Antigen (PSA) Protein Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Serum 23356551
1054 Prostate Specific Antigen (PSA) Protein Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.001 Serum 23356551
1057 Testosterone Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 4.62 ±1.48; After: 0.15 ± 0.1) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1058 Dihydrotestosterone (DHT) Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 0.88 ±0.41 ; After: 0.05 ± 012) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1059 Dehydroepiandrosterone sulfate (DHEA-S) Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 133.3 ±63.8; After: 83.4 ± 51.4) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1060 Androstenedione Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 1.6 ±0.61 ; After: 0.83 ± 0.42) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1061 3α-diol-G Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 26.4 ±6.9 ; After: 5.4 ± 7.1) Predictive Before and after androgen Deprivation therapy (ADT) p<0.001 Serum 23374809
1062 Insulin-like growth factor 1 (IGF-I) Metabolites Humans Upregulated with Androgen Deprivation Therapy (Before: 19.9 ±7.7 ; After: 22.2 ±9.1 ) Predictive Before and after androgen Deprivation therapy (ADT) p=0.001 Serum 23374809
1063 1,25(OH)2D Metabolites Humans Downregulated with Androgen Deprivation Therapy (Before: 66.2 ±4.2 ; After: 59.7 ± 4.0) Predictive Before and after androgen Deprivation therapy (ADT) p=0.008 Serum 23374809
1064 miR-141 miRNA Humans Upregulated in Bone Metastasis Prognostic Patients with Bone Metastasis Vs No Bone Metastasis p<0.001 Serum 23377530
1103 Apolipoprotein B Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.01 Serum 23582881
1104 Biotinidase Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.041 Serum 23582881
1105 Cell adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.046 Serum 23582881
1106 Complement factor H Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.025 Serum 23582881
1107 Ceruloplasmin Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1108 Carboxypeptidase M Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.001 Serum 23582881
1109 Intercellular adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1110 Galectin-3-binding protein Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.009 Serum 23582881
1111 Serum paraoxonase/arylesterase 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.011 Serum 23582881
1112 Poliovirus receptor-related protein 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.046 Serum 23582881
1113 Thrombospondin-1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.022 Serum 23582881
1114 Transmembrane 9 superfamily member 3 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.037 Serum 23582881
1123 miR-24 miRNA Mice Upregulated in TRAMP Mice Diagnostic TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) VS Wild Type (WT) mice p < 0.01 Serum 23719956
1124 β-CTX (β-isomer of carboxiterminal telopeptide of collagen I) Protein Humans NA Predictive Survival Vs No Survival after treatment with zoledronic acid p = 0.0049 Serum 23722472
1125 P1NP (aminoterminal propeptide of procollagen I) Protein Humans NA Predictive Survival Vs No Survival after treatment with zoledronic acid p = 0.0139 Serum 23722472
1148 C-Reactive Protein (CRP) Protein Humans Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy) Prognostic Biochemical Failure Free survival p = 0.009 Serum 23818401
1149 Insulin Like Growth Factor Binding Proteins (IGFBP-3) Protein Humans Upregulated in Intervention Group Predictive Intervention Vs Control Group p = 0.002 Serum 23775525
1170 miR-141 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.007 Serum 23846169
1171 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.008 Serum 23846169
1172 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.044 Serum 23846169
1173 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.02 Serum 23846169
1174 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.029 Serum 23846169
1176 Prostate Health Index (phi) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No evidence of Maligancy p <0.001 Serum 23861782
1198 Angiogenin Protein Humans Upregulated in Patients with PCa (median): [Cancer 487,500 vs. Non Cancer: 414,800) Diagnostic Prostate Cancer Vs Non Cancer p = 0.008 Serum 23921786
1199 miR-210 miRNA Humans Upregulated in PCa [Cohort 1: 6.9 fold; Cohort 2: 3.1 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) p=0.022 Serum 23935962
1200 miR-141 miRNA Humans Upregulated in PCa [Cohort 1: 27.9 fold; Cohort 2: 5.1 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p<0.0001; Testing: p<0.001 Serum 23935962
1201 miR-200a miRNA Humans Upregulated in PCa [Cohort 1: 6.1 fold; Cohort 2: 1.76 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.007; Testing: p=NS Serum 23935962
1202 miR-200c miRNA Humans Upregulated in PCa [Cohort 1: 22.4 fold; Cohort 2: 2.56 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.017; Testing: p=NS Serum 23935962
1203 miR-375 miRNA Humans Upregulated in PCa [Cohort 1: 4.6 fold; Cohort 2: 11.27 fold] Diagnostic Controls Vs Metastatic Castration Resistant Prostate Cancer (mCRPC) Training: p=0.009; Testing: p=0.021 Serum 23935962
1219 Methylation Status of GSTP1 Methylation Humans Hypermethylated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Serum 24086370
1232 N-terminal propeptide of collagen type I (PINP) Protein Humans Upregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastatis P < 0.001 Serum 24179387
1242 iXip: [IgM] + [tPSA] Protein Humans Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098] Diagnostic Prostate Cancer Vs Controls p <0.001 Serum 24240583
1321 miR-25; miR-101;miR-628-5p miRNA Humans Differentially Expressed Diagnostic African Americans Vs Caucasian Americans with PCa p<0.05 Serum 24477576
1322 miR-25 miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p= 0.0109 Serum 24477576
1323 miR-101 miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p= 0.0006 Serum 24477576
1324 miR-628-5p miRNA Humans Downregulated in PCa Diagnostic African Americans Vs Caucasian Americans with PCa p<0.0001 Serum 24477576
1344 Bone Alkaline Phosphatase [BAP] Protein Humans Upregulated (Estimate: 0.16) Predictive Atrasentan Vs Placebo Arm at baseline to week 9 p<0.001 Serum 24565955
1345 C-terminal of type 1 collagen [CICP] Protein Humans Downregulated (Estimate: 0.16) Predictive Atrasentan Vs Placebo Arm at baseline to week 9 p<0.001 Serum 24565955
1346 Pyridinoline [PYD] Protein Humans Downregulated (Estimate: 0.16) Predictive Atrasentan Vs Placebo Arm at baseline to week 9 p<0.001 Serum 24565955
1347 Bone Alkaline Phosphatase [BAP] Protein Humans NA Prognostic Overall Survival Vs No Survival p<0.001 Serum 24565955
1348 C-terminal of type 1 collagen [CICP] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1349 Pyridinoline [PYD] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1350 N-telopeptides of type 1 collagen [NTx] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1420 Macrophage Colony Stimulating Factor (M-CSF) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1421 CC chemokine ligand 18 (CCL-18) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1422 Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1423 Ttumor Necrosis Factor Receptor Superfamily Member 6 (TNFRSF6) [FAS/TNFRSF6] Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1454 Prostate Health Index (phi) Protein Humans Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)] Diagnostic Negative Vs PCa (Segregated on the basis of Prostate Volume) Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009 Serum 24978824
1455 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Gleason Score p< 0.001 Serum 24992524
1456 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Prostate Cancer Stage p = 0.007 Serum 24992524
1458 Vascular Endothelial Growth Factor (VEGF) Protein Humans Upregulated in PCa (PCa: 356.3±181.1; BPH: 147.5±80; Healthy: 124.9±50.8) Diagnostic Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals) p<0.001 Serum 25032132
1459 Vascular Endothelial Growth Factor (VEGF) + Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa: [VEGF+ PSA] Diagnostic Prostate Cancer Vs (Benign prostatic hyperplasia + Healthy Individuals) NA Serum 25032132
1501 tPSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1502 p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1503 %p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1504 Prostate Health Index (PHI) Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1505 tPSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1506 p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1507 %p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1508 Prostate Health Index (PHI) Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1519 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA] Protein Humans Upregulated 4K Score in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer PSA >3ng/ml: p<0.01; All Patients: p<0.04 Serum 25168616
1520 PCA3 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer PSA >3ng/ml: p=0.01; All Patients: p<0.01 Serum 25168616
1521 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA]+ PCA3 Protein Humans Upregulated in Prostate Cancer Diagnostic Prostate Cancer Vs No Cancer NA Serum 25168616
1534 miRNA-21 miRNA Humans Upregulated in PCa( BPH: 1.3 ± 3.6; PCa:4.5 ± 3.6) Diagnostic Prostata Cancer Vs Benign prostatic hyperplasia p=0.003 Serum 25190021
1535 miRNA-221 miRNA Humans Upregulated in PCa( BPH: 1.2 ± 2.5; PCa: 6.9±4.6) Diagnostic Prostata Cancer Vs Benign prostatic hyperplasia p=0.004 Serum 25190021
1595 Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa [BPH: 7.2 (1.8-19.8); PCa: 7.7 (1.0-19.4)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p = 0.0407 Serum 26254378
1596 %fPSA Protein Humans Downregulated in PCa [BPH: 16.7 (1.8-45.4); PCa:11.7 (4.1-31.7)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.0001 Serum 26254378
1597 Prostate Health Index (phi) Protein Humans Upregulated in PCa [BPH: 35.1 (13.1-155.6); PCa:61.6 (17.0-231.8)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p<0.0001 Serum 26254378
1598 −2proPSA Protein Humans Upregulated in PCa [BPH: 16.0 (3.0-81.0); PCa: 21.0 (4.0-135.0)] Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia p = 0.0004 Serum 26254378
1666 tPSA Protein Humans Upregulated in PCa Cell Lines Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1667 %fPSA Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1668 p2PSA Protein Humans Downregulated in Primary and Metastatic PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1669 %p2PSA Protein Humans Upregulated in PCa (PCa: 6.7; No PCa: 6.01) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1670 PHI (Prostate Health Index) Protein Humans Downregulated in PCa (PCa in %: 13.5; No PCa in %: 17.6) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1671 tPSA + fPSA Protein Humans Upregulated in PCa (PCa: 14.92; No PCa: 11.79) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1672 tPSA + %fPSA Protein Humans Downregulated in PCa (PCa in %: 20.5 ; No PCa in %: 15.5) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1673 fPSA + p2PSA Protein Humans Upregulated in PCa (PCa: 48.62; No PCa: 33.35) Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1674 %fPSA + %p2PSA Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1675 PSA + %fPSA + %p2PSA Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1676 tPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1677 fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1678 p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1679 %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1680 %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1681 PHI Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1682 tPSA+ fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1683 tPSA+ %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1684 fPSA + p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1685 %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1686 PSA + %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1687 TIMP1 (Tissue Inhibitor Of Metalloproteinase 1) Protein Humans NA Diagnostic PCa Vs No PCa p=0.003 Serum 25967040
1688 sE-Cadherin Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25967040
1689 Clusterin Protein Humans NA Diagnostic PCa Vs No PCa p=0.004 Serum 25967040
1690 MMP9 Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25967040
1691 Galectin Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p=0.01 Serum 25967040
1692 sE-Cadherin Protein Humans Upregulated in PCa Prognostic Gleason Pattern 3 Vs 4 Vs 5 p=0.02 Serum 25967040
1693 sE-Cadherin Protein Humans Downregulated in PCa Prognostic Gleason Upgrade Vs No Gleason Upgrade p=0.03 Serum 25967040
1704 hsv1-miR-H18 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.004 Tissue+Urine+Serum 26126436
1705 hsv2-miR-H9-5p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue, Urine: p<0.001; Serum: p=0.002 Tissue+Urine+Serum 26126436
1706 hsa-miR-615-3p miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1707 hsa-miR-BARTA-4 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Tissue+Urine+Serum 26126436
1708 hsa-miR-4316 miRNA Humans Upregulated in PCa (Tissue, Serum, Urine) Diagnostic Prostate Cancer Vs Benign prostatic hyperplasia Tissue: p<0.001; Urine: p=0.022 Tissue+Urine+Serum 26126436
1723 Zn/PSA Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.0001 Serum 30672309
1726 HA: Hyaluronic acid Metabolites Humans Upregulated in PCa (PCa: 239.6 (145.1–357.7); No PCa: 150.8 (51.8–264.1)) Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.004 Serum 30516927
1727 HA: Hyaluronic acid Metabolites Humans NA Prognostic High Risk Vs Intermediate Risk PCa p=0.0214 Serum 30516927
1728 HA: Hyaluronic acid Metabolites Humans Upregulated in Patient Reclassification Predictive Before and After Surgery Levels p=0.029 Serum 30516927
1751 Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine Lipid Humans Upregulated in PCa: Fold change mean(BPH: 1.365; PCa: 10.108) Prognostic Biochemical recurrence Vs No Biochemical Recurrence NA Serum 30758971
1752 Gleason score+age,+pre-operative PSA +pathological stage+Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine Lipid Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence NA Serum 30758971
1761 CGA (chromogranin A) Protein Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0416 Serum 30286478
1762 miR-1825 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1763 miR-484 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1764 miR-205 miRNA Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1765 miR-141 miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1766 let-7b miRNA Humans Downregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.001 Serum 30324582
1767 miR-1825 miRNA Humans Downregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1768 let-7b miRNA Humans Upregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1769 miR-205 miRNA Humans Downregulated in PCa Prognostic Bone Metastasis Vs No Bone Metastasis p<0.05 Serum 30324582
1811 PHI (Prostate Health Index) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Serum 30926382
1812 PHID (Prostate Health Index Density) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Serum 30926382
1879 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Progression Free Survival Vs No Progression Free Survival p=0.037 Serum 30446464
1880 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0028 Serum 30446464
1881 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Overall Survival Vs No Overall Survival p=0.043 Serum 30446464
1882 Keratin, type II cytoskeletal 2 epidermal; Serum amyloid P‐component;Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 9; Isoform 2 of Filamin A; Isoform 3 of Vitamin D‐binding protein; Ig kappa chain V‐II region Cum; soform 2 of Eukaryotic translation initiation 1.8 factor 2‐alpha kinase 4; Ig alpha‐1 chain C region; Afamin; Protein Humans Increased in Progression Free survival Diagnostic Prostate Cancer in African American Men Vs Normal African American Men p<0.05 Serum 30623593
1883 Complement component C8 alpha chain; Apolipoprotein A‐I; Plasminogen; Complement component C7;Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4;Inter‐alpha‐trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain V‐III region BRO; Ig gamma‐2 chain C region; Ig gamma‐3 chain C region; Protein Humans Decreased in Progression Free Survival Diagnostic Prostate Cancer in African American Men Vs Normal African American Men p<0.05 Serum 30623593
1884 Complement component C8 alpha chain; Apolipoprotein A‐I; Plasminogen; Complement component C7;Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4;Inter‐alpha‐trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain V‐III region BRO; Ig gamma‐2 chain C region; Ig gamma‐3 chain C region; Protein Humans Decreased in Overall Survival Diagnostic Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men p<0.05 Serum 30623593
1885 SCO‐spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid P‐component; g heavy chain V‐I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2; Protein Humans Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid P‐component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin D‐binding protein (2.4 fold); Ig kappa chain V‐II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2‐alpha kinase 4 (1.8 fold) ; Ig alpha‐1 chain C region (1.7 fold) ; Afamin (1.5 fold); Diagnostic Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men p<0.05 Serum 30623593
1886 Isoform 2 of Eukaryotic translation initiation factor 2‐alpha kinase 4; Keratin type I cytoskeletal 10; SCO‐ spondin; Serum amyloid P‐component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain V‐IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal; Protein Humans Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein A‐I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4 (0.2 fold); Inter‐alpha‐trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain V‐III region BRO (0.2 fold); Ig gamma‐2 chain C region (0.2 fold); Ig gamma‐3 chain C region (0.2 fold);] Diagnostic African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) p<0.05 Serum 30623593
1887 Ig heavy chain V‐III region BRO; Alpha‐1‐antitrypsin; Plasminogen (0.1‐ fold); Ig heavy chain V‐III region TIL, Hemopexin; Afamin; Inter‐alpha‐trypsin inhibitor heavy chain H1; Protein AMBP; Alpha‐1B‐glycoprotein; Complement component C8 alpha chain; Protein Humans Upregulated in PCa [Alpha‐1‐acid glycoprotein 1 (13.6‐fold); Alpha‐1B‐glycoprotein (11.6‐fold); von Willebrand factor (5.0‐fold); Ig heavy chain V‐II region NEWM (6.0‐fold); Ig heavy chain V‐III region BRO (5.7‐fold); Afamin (5.4‐fold); Apolipoprotein A‐I (4.9‐fold); Isoform 3 of Vitamin D‐binding protein (4.3‐fold); Complement C1r subcomponent (4.3‐ fold); Angiotensinogen (4.1‐fold); Diagnostic African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) p<0.05 Serum 30623593
1919 miR-17* miRNA Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.040 Serum 25786615
1920 miR-200b* miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.045 Serum 25786615
1921 miR-210 miRNA Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.003 Serum 25786615
1922 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.27 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.031 Serum 25786615
1923 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.13 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.009 Serum 25786615
1924 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.02 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.015 Serum 25786615
1925 miR-551b miRNA Humans Upregulated in PCa [mean PC/mean]: (2.30 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.017 Serum 25786615
1926 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (14.66 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.01 Serum 25786615
1927 miR-562+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.12 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1928 miR-562+ miR-210+ miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (17.39 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1929 miR-562+ miR-210+ miR-501-3p+ miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.72 fold) Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1930 miR-562+ miR-210+ miR-501-3p+ miR-375+ miR551b miRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic hyperplasia NA Serum 25786615
1931 let-7a* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.012 Serum 25786615
1932 miR-200b* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1933 miR-210 miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.01 Serum 25786615
1934 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.038 Serum 25786615
1935 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.014 Serum 25786615
1936 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1937 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.03 Serum 25786615
1938 miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.05 Serum 25786615
1939 let-7a*+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1940 let-7a*+ miR-210+ miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1941 let-7a*+ miR-210+ miR-562+ miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1942 let-7a*+ miR-210+ miR-562+ miR-616+ miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615